Abstract
There are many different signaling pathways that contribute to development and cellular homeostasis. In diseases, especially cancer, development components of these pathways often become mutated or overexpressed causing dysregulation of cellular signaling. This chapter provides an overview of the key pathways involved in tumor development and progression and studies some of the complications associated with therapeutic targeting, namely, signaling cross talk and biomarker identification.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Hanahan D, Wienberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.
Cruickshanks N, Zhang Y, Yuan F, Pahuski M, Gibert M, Abdounder R. Role and therapeutic targeting of the HGF/MET pathway in glioblastoma. Cancer. 2017;9:87–102.
Westermark B. Platelet-derived growth factor in glioblastoma—driver or biomarker? Ups J Med Sci. 2014;119:298–305.
Slebioda TJ, Kmiec Z. Tumour necrosis factor superfamily members in the pathogenesis of inflammatory bowel disease. Mediat Inflamm. 2014;2014:325129.
Keppler-Noreuil KM, Parker VER, Darling TN, Martinez-Agosoto JA. Somatic growth disorders of the PI3K/AKT/mTOR pathways and therapeutic strategies. Am J Med Genet. 2016;172C:402–21.
Hare SH, Harvey AJ. mTOR function and therapeutic targeting in breast cancer. Am J Cancer Res. 2017;7(3):383–404.
Cristea S, Sage J. Is the canonical RAF/MEK/ERK signaling oath way a therapeutic target in SCLC. J Thorac Oncol. 2016;11(8):1233–41.
McCubrey JA, Rakus D, Gizak A, Steelman LS, Abrams SL, Lertpiriyapong K, et al. Effects of mutations in the Wnt/β-catenin, hedgehog, notch and PI3K pathways on GsK-3 activity – diverse effects on cell growth, metabolism and cancer. Biochim Biophys Acta. 2016;1863:2942–76.
Bosman MCJ, Schuringa JJ, Vellenga E. Constitutive NK-κB activation in AML: causes and treatment strategies. Crit Rev Oncol. 2016;98:35–44.
Choudary I, Barr PM, Friedberg J. Recent advances in the development of Aurora kinases inhibitors in hematological malignancies. Ther Adv Hematol. 2015;6(6):282–94.
Harvey AJ. Signalling cross talk. In: Harvey AJ, editor. Cancer cell signalling. Chichester: Wiley Blackwell; 2013. p. 193–206.
Montemurro F, Scaltriti M. Biomarkers of rugs targeting HER-family signaling in cancer. J Pathol. 2014;232:219–29.
Augustine TA, Baig M, Sood A, Budagov T, Atzmon G, Mariadason JM, Aparo S, Maitra R, Goel S. Telomere length is a novel predictive biomarker of sensitivity to anti-EGFR therapy in metastatic colorectal cancer. Br J Cancer. 2015;112:313–8.
Yang J, Li S, Wang B, Wu Y, Chen Z, Lv M, et al. Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer. Tumour Biol. 2016;37:11645–55.
Hussain HA, Harvey AJ. Evolution of breast cancer therapeutics: breast tumour kinase’s role in breast cancer and hope for breast tumour kinase targeted therapy. World J Clin Oncol. 2014;5(3):299–310.
Martin M, Wei H, Tao L. Targeting the microenvironment in cancer therapeutics. Oncotarget. 2016;7(32):52272–583.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Harvey, A.J. (2019). Overview of Cell Signaling Pathways in Cancer. In: Badve, S., Kumar, G. (eds) Predictive Biomarkers in Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-95228-4_12
Download citation
DOI: https://doi.org/10.1007/978-3-319-95228-4_12
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-95227-7
Online ISBN: 978-3-319-95228-4
eBook Packages: MedicineMedicine (R0)